Get the Stockscreener App
77.16
2.28%
-1.80
After Hours:
77.16
Celcuity Inc stock is traded at $77.16, with a volume of 1.01M.
It is down -2.28% in the last 24 hours and up +56.19% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$78.96
Open:
$79.03
24h Volume:
1.01M
Relative Volume:
0.88
Market Cap:
$3.27B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-28.79
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+8.72%
1M Performance:
+56.19%
6M Performance:
+592.64%
1Y Performance:
+397.81%
1-Day Range:
$76.42
$79.97
1-Week Range:
$71.50
$80.13
52-Week Range:
$7.575
$83.00
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
77.16 | 3.35B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
How to track smart money flows in Celcuity Inc.2025 Analyst Calls & Detailed Earnings Play Strategies - newser.com
What drives Celcuity Inc stock priceTechnical Analysis Insights & Build Diversified Portfolios With Ease - earlytimes.in
Sector ETF performance correlation with Celcuity Inc.Gap Up & Safe Capital Allocation Plans - newser.com
Will Celcuity Inc. stock benefit from AI adoption2025 Volatility Report & Precise Swing Trade Entry Alerts - newser.com
Price action breakdown for Celcuity Inc.Weekly Trend Report & AI Based Trade Execution Alerts - newser.com
Why analysts upgrade Celcuity Inc. stockQuarterly Market Summary & Daily Oversold Stock Bounce Ideas - newser.com
What institutional flow reveals about Celcuity Inc.Market Sentiment Summary & Fast Moving Stock Trade Plans - newser.com
Candlestick signals on Celcuity Inc. stock todayJuly 2025 Institutional & Expert Approved Trade Ideas - newser.com
How buybacks impact Celcuity Inc. stock valueTrade Signal Summary & Safe Entry Trade Signal Reports - newser.com
Celcuity (CELC) Is Up 11.9% After Revealing Efficacy of Gedatolisib in ESMO Trial Results - simplywall.st
Celcuity : Corporate Presentation (Celcuity Investor Presentation V.7.1.2 Final) - MarketScreener
Celcuity (CELC) Price Target Increased by 10.74% to 84.15 - Nasdaq
When is the best time to exit Celcuity Inc.Oil Prices & Reliable Entry Point Trade Alerts - newser.com
How currency fluctuations impact Celcuity Inc. stockEarnings Beat & Technical Buy Zone Confirmation - newser.com
What analysts say about Celcuity Inc stockVolatility Trading Techniques & Grow Steadily With Our Wealth Roadmap - earlytimes.in
Published on: 2025-10-27 20:00:39 - newser.com
Is It Too Late to Buy Celcuity Stock? - StocksToTrade
Celcuity Inc.’s Promising Phase 3 Breast Cancer Study: A Market Game-Changer? - TipRanks
Celcuity’s Phase 3 Breast Cancer Study: A Potential Game-Changer? - TipRanks
Celcuity Shares Surge Amid Promising Cancer Study - TipRanks
Celcuity Inc.’s Promising Study on mCRPC Treatment: Key Insights for Investors - TipRanks
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):